الفهرس 
Comparative study between colistin and colistin-combined therapy in treatment
Abstract EnglishOnly 14 pages are availabe for public view
 |  | from | 146 |  |  |
| | | from | 146 | | |
Abstract
In clinical practice, colistin is used as a combination therapy to improve its antibacterial activity, despite the consequent increase in toxicity. This pilot prospective study aimed to evaluate the effectiveness and adverse effects of using colistin alone at a loading dose of 9 million international units (MIU), followed by 3 MIU/q8h vs colistin with meropenem 1 g/q8h in treating multidrug-resistant (MDR) Klebsiella pneumoniae-induced hospital-acquired pneumonia (HAP) or ventilator-associated pneumonia (VAP). The primary outcome measure was the in- hospital mortality and the second was the occurrence of colistin toxicity. Sixty patients were divided into 2 groups (30 patients each); the first group received intravenous colistin with mean daily dose of 8.304 MIU, whereas the second group received colistin 8.58 MIU combined with meropenem (mean daily dose of 2.88 g for 15 days). The colistin-meropenem combined treated group revealed a significant decrease in mortality (5/30, 16.67%) vs colistin alone (13/30, 43.33%, P=0.047)